Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice

Journal of Human Virology

Volumn 2, Issue 2, 1999, Pages 102-114

  Leipner, Carola ^a,b   Borchers, Michael ^a   Merkle, Ingrid ^a   Stelzner, Axel ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

CD4+ T cells; Coxsackievirus B3; MHC class II knockout mice; Myocarditis

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3; DISEASE COURSE; HISTOLOGY; IMMUNE DEFICIENCY; IMMUNOHISTOLOGY; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; GENE DELETION; HEART; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOLOGIC TECHNIQUES; LYMPHOCYTE COUNT; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MYOCARDITIS; MYOCARDIUM; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

ANIMALIA; COXSACKIEVIRUS;

EID: 0033508486     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Friman G, Wesslén L, Fohlman J, Karjalainen J, Rolf C. The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J 1995;16:36-41.
2. Hosenpud JD, Novick RJ, Breen TJ, Daily OP. The registry of the International Society for Heart and Lung Transplantation: eleventh report - 1994. J Heart Lung Transplant 1994;13:561-570.
3. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy. AmJ Cardiol 1992;69:1458-1466.
4. Tracy S, Chapman NM, McManus BM, Pallansch MA, Beck MA, Carstens J. A molecular and serologic evaluation of enteroviral involvement in human myocarditis. J Mol Cell Cardiol 1990;22:405-414.
5. Bowles NE, Richardson PJ, Olsen EGJ, Archard LC. Detection of coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986;1:1120-1123.
6. Kandolf R, Ameis D, Kirchner P, Canu A, Hofschneider PH. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 1987;84:6272-6276.
7. Kühl U, Noutsian M, Seeberg H, Schultheiß H-P. Immunhistochemical evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 1996;75:295-300.
8. Melnick JL. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields BN, Knipe DM, Howley PM, et al, eds. Virology. Philadelphia: Lippincott-Raven, 1996:655-712.
9. Cherry JD. Enteroviruses. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant, 3rd ed. Philadelphia: WB Saunders, 1990:325-366.
10. Rose NR, Neumann DA, Herskowitz A. Coxsackievirus myocarditis. In: Advances in internal medicine, vol. 37. St. Louis: Mosby-Year Book, 1992:411-429.
11. Rabausch-Starz I, Schwaiger A, Grunewald K, Muller-Hermelink HK, Neu N. Persistence of virus and viral genome in myocardium after coxsackievirus B3-induced murine myocarditis. Clin Exp Immunol 1994;96:69-74.
12. Gauntt CJ, Tracy SM, Chapman N, et al. Coxsackievirus-induced chronic myocarditis in murine models. Eur Heart J 1995;16:56-58.
13. Kandolf R, Klingel K, Zell R, et al. Molecular pathogenesis of enterovirus-induced myocarditis: virus persistence and chronic inflammation. Intervirology 1993;35:140-151.
14. Gauntt C, Higdon A, Bowers D, Maull E, Wood J, Crawley R. What lessons can be learned from animal model studies in viral heart disease? Scand J Infect Dis 1993; 88(Suppl):49-65.
15. Woodruff JF, Woodruff JJ. Involvement of T-lymphocytes in the pathogenesis of coxsackievirus B3 heart disease. J Immunol 1974;113:1726-1734.
16. + cytolytic lymphocytes. Cell Immunol 1984;88:558-567.
17. Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in Balb/c mice: evidence for autoimmunity to myocyte antigens. AmJ Pathol 1984;116:21-29.
18. + T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 1995;69:6720-6728.
19. Woodruff JF. Viral myocarditis: a review. Am J Pathol 1980;101:425-484.
20. Königen F, Süss G, Stewart C, Steinmetz M, Bluethmann H. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol 1993;8:957-964.
21. Reed LJ, Muench HA. A simple method of estimating per cent endpoints. Am J Hyg 1938, 27:493-497.
22. Arnold B, Messerle M, Jatsch L, Küblbeck G, Koszinowski U. Transgenic mice expressing a soluble foreign H-2 class I antigen are tolerant to allogeneic fragments presented by self class I but not to the whole membrane-bound alloantigen. Proc Natl Acad Sci U S A 1990;87:1762-1766.
23. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. Interleukin 1 or tumor necrosis factor can promote coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med 1992;175:1123-1129.
24. Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldmann AM. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail 1997;3:117-124.
25. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardicmyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81:627-635.
26. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor alpha. Circulation 1998;97:1375-1381.
27. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A 1992;89:314-318.
28. Satoh M, Tamura G, Segawa I, Hiramori K, Satodate R. Enteroviral RNA in dilated cardiomyopathy. Eur Heart J 1994;15:934-939.
29. Satoh M, Tamura G, Segawa I, Tashiro A, Hiramori K, Satodate R. Expression of cytokine genes and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated cardiomyopathy. Virchows Arch 1996;427:503-509.
30. Huber SA, Haisch C, Lodge PA. Coxsackievirus-induced myocarditis: model for picornavirus-induced autoimmunity. Semin Virol 1990;1:289-295.
31. Hashimoto I, Komatsu T. Myocardial changes after infection with coxsackie virus B3 in nude mice. Br J Exp Pathol 1978;59:13-20.
32. Hashimoto I, Tatsumi M, Nakagawa M. The role of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. Br J Exp Pathol 1983;64:497-504.
33. Gomez MP, Reyes MP, Smith F, Ho LK, Lerner AM. Coxsackievirus B3-positive mononuclear leukocytes in peripheral blood of Swiss and athymic mice during infection. Proc Soc Exp Biol Med 1980;165:107-113.
34. Robinson JA, O'Connell JB, Roeges LM, Major EO, Gunnar RM. Coxsackie B3 myocarditis in athymic mice. Proc Soc Exp Biol Med 1981;166:80-91.
35. Schnurr DP, Cao Y, Schmidt NJ. Coxsackievirus B3 persistence and myocarditis in N:NIH(S) II nu/nu and +/nu mice. J Gen Virol 1984;65:1197-1201.
36. Sato S, Tsutsumi R, Burke A, et al. Persistence of replicating coxsackievims B3 in the athymic murine heart is associated with development of myocarditic lesions. J Gen Virol 1994;75:2911-2924.
37. Andreoletti L, Hober D, Becquart P, et al. Experimental CVB3-induced chronic myocarditis in two murine strains: evidence of interrelationships between virus replication and myocardial damage in persistent cardiac infection. J Med Virol 1997;52:206-214.
38. Huber SA, Job LP. Differences in cytolytic T cell response of Balb/c mice infected with myocarditic and nonmyocarditic strain of coxsackievirus group B, type 3. Infect Immun 1983;39:1419-1427.
39. Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. J Pathol 1984;116:21-29.
40. Lodge PA, Herzum M, Olszewski J, Huber SA. Coxsackievirus B-3 myocarditis: acute and chronic forms of the disease caused by different immunopathogenic mechanisms. AmJ Pathol 1987;128:455-463.
41. Chow LH, Gauntt CJ, McManus BM. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice: a pathologic characterization of heart tissue damage. Lab Invest 1991;64:55-64.
42. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487-1493.
43. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-ot and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711.
44. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-566.
45. Beutler B. TNF, immunity, and inflammatory disease: lessons of the past decade. J Invest Med 1995;43:227-235.
46. Seko Y, Tsuchimochi H, Nakamura T, et al. Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with coxsackievirus B3. Circ Res 1990;67:360-367.
47. Seko Y, Yamazaki T, Shinkai Y, et al. Cellular and molecular bases for the immunopathology of the myocardial cell damage involved in acute viral myocarditis with special reference to dilated cardiomyopathy. Jpn Circ J 1992; 56:1062-1072.
48. Herskowitz A, Ahmed-Ansari A, Neumann DA, et al. Induction of major histocompatibility complex antigens within the myocardium of patients with active myocardilis: a nonhistologic marker of myocarditis. J Am Coll Cardiol 1990;15:624-632.
49. Rager-Zisman B, Allison AC. The role of antibody and host cells in the resistance of mice against infection by coxsackie B-3 virus. J Gen Virol 1973;19:329-338.
50. Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model: antiviral and anti-inflammatory effects. Circulation 1995;92:1604-1611.
51. Woodruff JF. Lack of correlation between neutralizing antibody production and suppression of coxsackievirus B-3 replication in target organs: evidence for involvement of mononuclear inflammatory cells in host defense. J Immunol 1979;123:31-36.
52. + T-helper and a T-killer cell. Nature 1998;393:474-478.
53. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-480.
54. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CDL interactions. Nature 1998;393: 480-483.
55. Milei J, Grana D, Alonso GF, Matturri L. Cardiac involvement in acquired immunodeficiency syndrome - a review to push action. Clin Cardiol 1998;21:465-472.
56. Yunis NA, Stone VE. Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18: 145-154.
57. Cohen IS, Anderson DW, Virmani R, et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 1986;315:628-630.
58. Anderson DW, Virmani R. Emerging patterns of heart disease in human immunodeficiency virus infection. Hum Pathol 1990;21:253-259.
59. LongoMbenza B, Seghers KV, Phuati M, Bikangi FN, Mubagwa K. Heart involvement and HIV infection in African patients: determinants of survival. Int J Cardiol 1998;64:63-73.
60. Herskowitz A, Willoughby SB, Vlahov D, Baughman KL, Ansari AA. Dilated heart muscle disease associated with HIV infection. Eur Heart J 1995;16:50-55.